Cargando…

Remicade(®) (infliximab): 20 years of contributions to science and medicine

On August 24, 1998, Remicade(®) (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn’s disease. Subsequently, Remicade was approved in another five adult and two pediatric indicati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melsheimer, Richard, Geldhof, Anja, Apaolaza, Isabel, Schaible, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679695/ https://www.ncbi.nlm.nih.gov/pubmed/31440029 http://dx.doi.org/10.2147/BTT.S207246

Ejemplares similares

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade(®)
por: Melsheimer, Richard, et al.
Publicado: (2018)

The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review
por: Nahra, Vicky, et al.
Publicado: (2020)

A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects
por: Shin, Donghoon, et al.
Publicado: (2015)

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade(®))
por: Kim, Soohyun, et al.
Publicado: (2020)

Twenty Years of Quiescence after Nonstop Remicade(®) (Infliximab) Infusions in a Child with Ocular Behçet Disease Presenting as Hypopyon-Anterior Uveitis Refractory to Immunosuppressants
por: Evereklioglu, Cem
Publicado: (2023)

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
por: Tanaka, Y, et al.
Publicado: (2010)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents
por: Reinisch, Walter, et al.
Publicado: (2017)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
por: Magro, F., et al.
Publicado: (2018)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

Exposure to Infliximab During Pregnancy: Post-Marketing Experience
por: Geldhof, Anja, et al.
Publicado: (2019)

Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques
por: Fang, Jing, et al.
Publicado: (2016)

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade(®) to Remsima(®)? An Observational Study
por: Xue, Laixi, et al.
Publicado: (2020)

Infliximab: 12 years of experience
por: Smolen, Josef S, et al.
Publicado: (2011)

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017)

Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease
por: Smits, Lisa J. T., et al.
Publicado: (2017)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
por: Vander Cruyssen, Bert, et al.
Publicado: (2005)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

The contributions of insulin to science in medicine
por: Kurtzhals, Peter, et al.
Publicado: (2021)

Tracing Makerere University's 100 years' contribution to lung science/medicine
por: Kirenga, Bruce J, et al.
Publicado: (2022)

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
por: Cruyssen, Bert Vander, et al.
Publicado: (2006)

Reflections on 20 years of RNA science
por: Feig, Andrew
Publicado: (2015)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Treatment of severe psoriasis with infliximab
por: Leman, JA, et al.
Publicado: (2008)

Infliximab in the treatment of rheumatoid arthritis
por: Perdriger, A
Publicado: (2009)

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Infliximab for the treatment of plaque psoriasis
por: Gall, Jennifer S, et al.
Publicado: (2008)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Collaborating on Data, Science, and Infrastructure: The 20-Year Journey of the Cancer Research Network
por: Doria-Rose, V. Paul, et al.
Publicado: (2019)

The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
por: Afzali, Anita, et al.
Publicado: (2021)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Infliximab in the treatment of plaque type psoriasis
por: Saraceno, Rosita, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_atp7vpkm1onlm2ft9ol01ql3fr